Artificial Intelligence
KidneyIntelX in Multi-Center Study to Monitor and Predict Kidney Risk in COVID-19 Patients
Surge in Chronic Kidney Disease and Kidney Failure Expected Post-COVID-19
Mount Sinai-Led Study to Assess 4,000 Surviving COVID-19 Patients
NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) — Mount Sinai Health System and Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), announce the initiation of a multi-center study to conduct in-depth investigations into kidney-related complications and long-term outcomes linked to COVID-19. KidneyIntelX, the artificial intelligence-enabled in vitro diagnostic platform, will be used to assess the risk of kidney disease progression and kidney failure, among other kidney complications, in patients surviving COVID-19 from multiple centers in the United States. As of July 30, 2020, over 300,000 Americans had been hospitalized for COVID-19.1
The study, titled “Multi-center Assessment of Survivors for Kidney Disease after COVID-19 (MASKeD-COVID),” expands on the Pred-MAKER study previously announced April 20, 2020 which focuses on the impact of COVID-19 in the acute hospitalized setting (https://renalytixai.com/kidneyintelx-covid-19/). Investigative teams expected to participate in the study include the Mount Sinai Health System Icahn School of Medicine at Mount Sinai in New York, Yale New Haven Health/Yale School of Medicine, Michigan Medicine/University of Michigan Medical School, Johns Hopkins Medicine/The Johns Hopkins University Medical School, and Rutgers, The State University of New Jersey/Rutgers New Jersey Medical School.
KidneyIntelX will be used to assess risk for new chronic kidney disease (CKD) in the short-term or kidney disease progression over the longer-term in patients who have recovered from COVID-19. Diverse data inputs, including validated blood and urine-based biomarkers, inherited genetics and extensive patient data from electronic health record systems, will be incorporated into the KidneyIntelX machine learning-enabled algorithm to generate a unique patient risk score. In addition, Mount Sinai Health System’s high-performance serologic SARS-CoV-2 testing will be used to assess a patient’s antibody levels to COVID-19 over time, providing valuable insights into the interaction between immune response and kidney-related complications in this patient population.
“With the pandemic spread of COVID-19 and the increased morbidity and mortality from COVID-19 in patients with diabetes, CKD and acute kidney injury, it is imperative to define the underlying mechanisms of COVID-associated kidney disease and develop solutions to guide patient care,” said F. Perry Wilson, M.D., MSCE, MASKeD-COVID Principal Investigator, Yale School of Medicine. “This can be best achieved through collaboration in all aspects including data sharing, biomarker analysis, data analytics and clinical translation. RenalytixAI and Mount Sinai have assembled an outstanding team to address critical issues regarding COVID-19 and kidney disease.”
“This collaborative approach is vital for us to further develop some important findings by the respective groups to date,” said Matthias Kretzler, M.D., MASKeD-COVID Principal Investigator at University of Michigan. “We have demonstrated that ACE2 (the SARS-CoV-2 receptor) is co-expressed with a set of genes in the proximal tubules also having functions in viral entry, establishment of viral replication, and innate immunity.2 We look forward to working with this outstanding team to further expand on this research and further define the underlying mechanisms of COVID-associated kidney disease.”
SARS-CoV-2 is believed to result in acute kidney injury through multiple mechanisms, including severe inflammation, endothelial damage, microthrombi, and possibly direct invasion of the virus into kidney epithelial cells.3 The burden and incidence of post-COVID-19 CKD and end-stage kidney disease (ESKD) is currently unknown, given the recency of the pandemic. However, emerging evidence suggests patients surviving COVID-19 will experience a significant increased risk of kidney disease, including the following:
- Approximately 20% to 45% of patients hospitalized with COVID-19 in the United States and over 60% of patients admitted to the ICU for COVID-19 in the United States experience acute kidney injury (AKI), approximately 25% to 45% of whom require acute dialysis;4
- Data from an analysis of over 3,000 patients admitted to Mount Sinai indicates that 50% of surviving patients who experienced AKI during hospitalization for COVID-19 had persistently abnormal kidney function at the time of discharge;5
- It has been established in the literature that AKI is strongly associated with development of CKD, CKD progression, and ESKD;6
- Given the observed severity of kidney injury in many COVID-19 patients, both clinically and histopathologically, the risk for subsequent transition to CKD and ESKD is likely to be high in survivors.7
“There are so many questions yet to be answered regarding COVID-19 and kidney disease. For example, we don’t yet know the risk factor and mediators of AKI to CKD transition after COVID-19. We also don’t know the predictors of long-term outcomes after COVID-19,” said Evren Azeloglu, Ph.D., Assistant Professor of Nephrology and Pharmacological Sciences at the Icahn School of Medicine at Mount Sinai. “Moreover, we need to understand how this “second hit” from COVID-19 interacts with other risk factors such as underlying APOL1 genotypes to heighten the potential for proteinuric nephropathy. Additional work with biomarker research, kidney tissue histopathology, and gene expression signatures is needed to understand the disease and the long-term implications.”
The MASKeD-COVID study will be coordinated by Mount Sinai, which has already implemented a COVID-19 Center of Excellence Registry and begun longitudinal follow-up with detailed assessments along with biospecimens collection.8 Initial research findings are expected to be reported in late 2020, with the goal of launching KidneyIntelX commercialization activities in this COVID-19 population targeted for H1 2021.
About the Mount Sinai Health System
The Mount Sinai Health System is New York City’s largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care—from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report’s “Honor Roll” of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians are in the top 1% of all physicians nationally by U.S. News & World Report.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.
About RenalytixAI
RenalytixAI is a commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management in CKD to help drive improved patient outcomes and significantly lower healthcare costs. KidneyIntelX, our first-in-class diagnostic platform, employs a proprietary artificial intelligence-enabled algorithm that combines diverse data inputs, including validated blood-based biomarkers, inherited genetics and extensive personalized patient data from electronic health record, or EHR, systems to generate a unique patient risk score. KidneyIntelX is based on technology developed by Mount Sinai faculty and licensed to RenalytixAI. Mount Sinai and Mount Sinai faculty have a financial interest in RenalytixAI.
Notes:
1 https://covidtracking.com/data/download
2 https://www.medrxiv.org/content/10.1101/2020.05.09.20096511v1
3, 4 http://www.nephjc.com/news/covidaki
5 https://www.medrxiv.org/content/10.1101/2020.05.04.20090944v1
6 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3788581/
7 https://jasn.asnjournals.org/content/31/7/1380
8 https://www.fiercehealthcare.com/hospitals-health-systems/mount-sinai-launches-post-covid-care-center-for-ongoing-treatments
Forward-Looking Statements
Certain statements made in this press release are forward-looking statements including with respect to the admission of the new ordinary shares to trading on AIM. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including if the new ordinary shares are not admitted to trading on AIM or admission is delayed. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this press release. The forward-looking statements made in this press release relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
For readers in the European Economic Area (“EEA”) and the United Kingdom
In any EEA member state and the United Kingdom, this communication is only addressed to and directed at qualified investors in that member state and the United Kingdom within the meaning of the Prospectus Regulation. The term “Prospectus Regulation” means Regulation (EU) 2017/1129.
For readers in the United Kingdom
This communication, in so far as it constitutes an invitation or inducement to enter into investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000 as amended (“FSMA”)) in connection with the securities which are the subject of the offering described in this press release or otherwise, is being directed only at (i) persons who are outside the United Kingdom or (ii) persons who have professional experience in matters relating to investments who fall within Article 19(5) (“Investment professionals”) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) certain high value persons and entities who fall within Article 49(2)(a) to (d) (“High net worth companies, unincorporated associations etc.”) of the Order; or (iv) any other person to whom it may lawfully be communicated (all such persons in (i) to (iv) together being referred to as “relevant persons”). The ADSs or ordinary shares offered in the Global Offering are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such ADSs or ordinary shares will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. This communication does not contain an offer or constitute any part of an offer to the public within the meaning of sections 85 and 102B of FSMA or otherwise.
Not for release, publication or distribution, in whole or in part, in or into or from any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as “may,” “will,” “could,” “expects,” “plans,” “anticipates,” and “believes.” These statements include, but are not limited to, statements regarding the conduct, design and timing of the MASKeD-COVID clinical trial, including the timing of initial research findings and the timing and viability of commercialization of KidneyIntelX in the COVID-19 population, as well as the participation of other institutions in the MASKeD-COVID clinical trial and the potential benefits of KidneyIntelX in assessing kidney disease in the context of COVID-19. Any forward-looking statements are based on management’s current views and assumptions and involve risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. We may not actually achieve the plans and objectives disclosed in the forward-looking statements, and you should not place undue reliance on our forward-looking statements. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements, including those described in the “Risk Factors” section of our final prospectus filed with the Securities and Exchange Commission (SEC) on July 17, 2020 and other filings we make with the SEC from time to time. All information in this press release is as of the date of the release, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.
For further information, please contact:
Renalytix AI plc | www.renalytixai.com | |
James McCullough, CEO | Via Walbrook PR | |
Stifel (Nominated Adviser, Joint Broker) | Tel: 020 7710 7600 | |
Alex Price / Nicholas Moore | ||
Walbrook PR Limited | Tel: 020 7933 8780 or [email protected] | |
Paul McManus / Lianne Cawthorne | Mob: 07980 541 893 / 07584 391 303 |
U.S. Media Contact:
Jennifer Moritz
Zer0 to 5ive for RenalytixAI
(917) 748-4006
[email protected]
Artificial Intelligence
Enghouse announces expansion of our cloud contact center technology in the Middle East through our partnership with Voxtron
MARKHAM, ON, May 6, 2024 /PRNewswire/ — Enghouse Interactive, a global leader in contact center and video technology solutions, is proud to announce a strategic partnership with Voxtron, the premier provider of call center solutions in the Middle East. This collaboration is marked by Voxtron’s introduction of the innovative Voxvantage Cloud Contact Center as a Service (CCaaS), leveraging advanced contact center technology from Enghouse.
The Official Launch will take place at the Grand Hyatt Dubai. Industry participants and media are invited to RSVP to attend by emailing [email protected].
Date: 9th May 2024 Time: 6:00 PM to 10:00 PM Venue: Grand Hyatt Dubai, RSVP: [email protected]
Voxvantage CCaaS marks a significant advancement for Enghouse Systems, underscoring a commitment to enhancing customer experiences throughout the region. Hosted on the robust data center infrastructure of Moro Hub, Voxtron guarantees exceptional reliability, security, and scalability.
The launch will feature distinguished speakers, including Tracy Reynolds, Canadian Consul General in Dubai, Vincent Mifsud, Global President of Enghouse Systems, and Arif AlMalik, Chief Digital Products Officer of Moro Hub. They will explore the transformative potential of contact solutions in improving customer experience (CX) in the Middle East.
Mr. Mifsud expressed his enthusiasm about the partnership, stating, “We are excited to collaborate with Voxtron and Moro Hub. This partnership is crucial as we aim to provide our call center technology, enhance our presence across the Middle East by providing customers with leading technology that improves customer experiences.”
The event will also offer excellent networking opportunities and insightful discussions on the future of customer engagement solutions.
About Enghouse Interactive:
Enghouse Interactive, a subsidiary of Enghouse Systems Limited, is a global leader in contact center software and video technology solutions offering its customers and partners the valuable advantage of choice. Enghouse Interactive empowers businesses to transform contact centers from cost centers into powerful growth engines by simplifying complex integrations through open standards and supporting various telephony technologies to ensure seamless customer accessibility across channels and locations.
About Voxtron:
Voxtron Middle East is headquartered in Dubai, U.A.E., and has a global presence with offices and affiliates in Qatar, India, Germany, Austria, Belgium, Italy, Turkey, Tunisia, Hong Kong, Portugal, and Thailand. Voxtron has been delivering cost-effective customer engagement optimization solutions in collaboration with leading technology vendors such as Enghouse Interactive, SAGE, Verint, and Clarabridge, for over a decade. This extensive portfolio positions Voxtron as a unique provider capable of delivering complete, fully-featured solutions to customers and partners.
Enghouse Video Contact: Tim Peters, VP, Global Demand Generation Leader, Enghouse Systems, [email protected]
View original content:https://www.prnewswire.co.uk/news-releases/enghouse-announces-expansion-of-our-cloud-contact-center-technology-in-the-middle-east-through-our-partnership-with-voxtron-302136981.html
Artificial Intelligence
Appdome Named “Editor’s Choice for Mobile App Security” in Coveted Global InfoSec Awards during RSA Conference 2024
Appdome Wins in 12th Annual Global InfoSec Awards at #RSAC 2024
SAN FRANCISCO, May 6, 2024 /PRNewswire/ — Appdome, the mobile app economy’s one-stop shop for mobile app defense, is proud to announce it has won Editor’s Choice for Mobile App Security from Cyber Defense Magazine (CDM), the industry’s leading electronic information security magazine.
The Appdome platform is the first and only full lifecycle mobile app defense platform to automatically build, monitor and respond with any or all of 300+ mobile app defenses including security, anti-fraud, anti-malware, anti-cheat, anti-bot, geo compliance and social engineering for any mobile app in minutes with no SDK or coding required – all within the CI/CD pipeline. As a mobile app security engine for DevOps, Appdome enables mobile app developers, even those lacking security expertise, with an easy and fast way to secure all Android & iOS apps without any additional work. By automating security in the mobile pipeline, Appdome eliminates the cost and complexity of manually coding security, fraud and compliance features so mobile brands can confidently ship secure mobile apps faster with always-on protections to meet their critical mobile business needs.
“We’re proud to be recognized as Editor’s Choice for Mobile App Security by Cyber Defense Magazine in its 12th year of awarding the most prestigious and coveted cybersecurity award in the world,” said Tom Tovar, co-creator and CEO of Appdome. “With organizations battling unnecessary complexity from point products, the Appdome platform approach to mobile defense is leading the way to unify 300+ protections across security, anti-fraud, bot defense, mobile EDR, and compliance for all internal (employee) and external (consumer) facing mobile applications under a single pane of glass.”
“We scoured the globe looking for cybersecurity innovators that could make a huge difference and potentially help turn the tide against the exponential growth in cyber-crime. Appdome is absolutely worthy of Editor’s Choice for Mobile App Security coveted award and consideration for deployment in your environment,” said Yan Ross, Global Editor of Cyber Defense Magazine.
Appdome and all award winners located here: http://www.cyberdefenseawards.com/
Appdome continues to deliver waves of innovation in 2024 including:
Appdome Unveils World’s first Agentless Mobile EDR & MTDAppdome MOBILEBot ProtectionAppdome World’s First Real-Time Defense for Social EngineeringAppdome Revolutionizes Geo Defense for Mobile BrandsPlease join Appdome at the RSA Conference 2024 booth #2339 to see the award winning Appdome Platform in action!
Learn more at www.appdome.com.
About AppdomeThe Appdome mission is to protect every mobile app in the world and the people who use mobile apps in their lives and at work. Appdome provides the mobile industry’s only Unified Mobile App Defense platform, powered by a patented mobile coding engine, Threat-Events™ Threat-Aware UX/UI Control and ThreatScope™ Mobile XDR. Using Appdome, mobile brands eliminate complexity, ship faster and save money by delivering 300+ Certified Secure™ mobile app security, anti-malware, anti-fraud, mobile anti-bot, anti-cheat, geo compliance, MiTM attack prevention, code obfuscation, social engineering and other protections in Android and iOS apps with ease, inside the mobile DevOps and CI/CD pipeline. Leading financial, healthcare, government and m-commerce brands use Appdome to protect Android and iOS apps, mobile customers and mobile businesses globally. Appdome holds several patents including U.S. Patents 9,934,017 B2, 10,310,870 B2, 10,606,582 B2, 11,243,748 B2 and 11,294,663 B2. Additional patents pending.
About Cyber Defense MagazineCyber Defense Magazine is the premier source of cyber security news and information for InfoSec professions in business and government. We are managed and published by and for ethical, honest, passionate information security professionals. Our mission is to share cutting-edge knowledge, real-world stories and awards on the best ideas, products, and services in the information technology industry. We deliver electronic magazines every month online for free, and special editions exclusively for the RSA Conferences. CDM is a proud member of the Cyber Defense Media Group. Learn more about us at https://www.cyberdefensemagazine.com and visit https://www.cyberdefensetv.com and https://www.cyberdefenseradio.com to see and hear some of the most informative interviews of many of these winning company executives. Join a webinar at https://www.cyberdefensewebinars.com and realize that infosec knowledge is power.
Logo – https://mma.prnewswire.com/media/772169/4688418/AppDome_Logo_9_27_23.jpg
View original content:https://www.prnewswire.co.uk/news-releases/appdome-named-editors-choice-for-mobile-app-security-in-coveted-global-infosec-awards-during-rsa-conference-2024-302136929.html
Artificial Intelligence
Generative AI Market Set for Meteoric Rise, Expected to Reach $266 Billion by 2032
USA News Group Commentary
Issued on behalf of Scope AI Corp.
VANCOUVER, BC, May 6, 2024 /PRNewswire/ — USA News Group – Despite a lack of consensus among thousands of experts on the development of artificial intelligence (AI) as it permeates the global economy, one thing is certain, AI is here to stay. According to analysts at Fintech Futures, the Generative AI Market expected to reach a revenue of US$266 billion by 2032, growing at an explosive CAGR of 37.8%. Behind the scenes of this AI-revolution, several tech companies are jockeying for position and adding new propositions for their clients, including developments from Scope AI Corp. (CSE: SCPE) (OTCQB: SCPCF), Cisco Systems, Inc. (NASDAQ: CSCO), Mobileye Global Inc. (NASDAQ: MBLY), Samsara Inc. (NYSE: IOT), and Veritone, Inc. (NASDAQ: VERI).
As the landscape of deep machine learning continues to evolve and reveal its potential across various sectors, Scope AI Corp. (CSE: SCPE) (OTCQB: SCPCF) has recently rebranded and expanded its target market to serve an expanding range of industries. Built upon its proprietary technology, GEM (General Enterprise Machine Learning), Scope recently updated the market regarding GEM’s latest advancements, which now include a one-stop web solution for developers and individuals, as well as businesses, large and small, to create, build, and use their own image detection, behavior analysis and neural network systems for their individual customer business cases.
The newly updated GEM Platform is a SaaS web application equipped with advanced user management tools for administrators or supervisors (CRM), enhanced security for logins and accounts, and comprehensive data encryption built directly into the system. Scope has initially targeted the advertising, gaming, and healthcare industries. The platform’s intuitive web interface allows businesses of any size to easily start and create tailored solutions. Additionally, a sophisticated Application Programming Interface (API) is set to be released later this year.
The new GEM system, set to launch its beta version in late May 2024, offers a comprehensive solution for businesses of any size to develop their own AI-driven object detection and visual information systems. This platform enables companies to experiment with how variations in visuals and user flows impact performance, leveraging the power of neural networks for a wide range of industry-specific applications.
In the field of AI-focused security, Cisco Systems, Inc. (NASDAQ: CSCO) recently launched its latest offering following its $28-billion acquisition of Splunk earlier this year. Dubbed ‘Hypershield’, the product employs AI to protect applications, devices and data across public and private data centers, clouds, and physical locations.
“Cisco Hypershield is one of the most significant security innovations in our history,” said Chuck Robbins, Chair and CEO of Cisco. “With our data advantage and strength in security, infrastructure and observability platforms, Cisco is uniquely positioned to help our customers harness the power of AI.”
Hypershield’s security enforcement operates at three distinct layers: within the software, across virtual machines, and throughout network and compute servers and appliances. This system utilizes the same advanced hardware accelerators that are commonly employed in high-performance computing environments and large-scale public clouds.
Helping to move the auto industry closer to universal automated assistance and navigation functionality, technology developed by Mobileye Global Inc. (NASDAQ: MBLY) will now be incorporated into vehicles made by both Volkswagen and Porsche. In the case of the Volkswagen deal, VW became the first vehicle manufacturer to develop an autonomous Level 4 service vehicle for large-scale production, after pulling out of its planned investment in Argo AI last year.
“Bringing autonomous shuttles on the road in large quantities requires cooperation from strong partners,” says Christian Senger, member of the Board of Management at Volkswagen Commercial Vehicles, responsible for Autonomous Driving. “We are developing the first fully autonomous large- scale production vehicle, and Mobileye brings its digital driver on board.”
By contrast, Porsche will implement Mobileye’s “Supervision” system, which allows drivers to take their hands off the wheel while traveling on certain road types, and allows the vehicle to follow navigation routes, change lanes, and even overtake slower vehicles ahead.
Quest Waste Management recently selected Samsara Inc. (NYSE: IOT) to provide its industry-leading AI dash cams to improve fleet safety. Samsara’s platform leverages Internet of Things (IoT) data to enable organizations involved in physical operations to gain insights and enhance their operational efficiency. Samsara’s AI Dash Cams and driver coaching tools are designed to provide significant benefits, such as reducing accidents, preventing false claims, and lowering operational costs.
“We look forward to providing [Quest] with the insights and real-time data they need to create a real-world impact on safety, for their employees, customers and the community within which they operate,” said Philip van der Wilt, senior vice president and general manager for Europe, Middle East and Africa (EMEA) at Samsara.
Quest reports having tens of thousands of clients throughout North America and Europe in various sectors, including construction, transportation and warehousing, field services, manufacturing, retail, logistics, and the public sector. In addition to establishing this new comprehensive fleet safety programme, Quest said it plans to also harness the capabilities of Samsara’s Connected Operations Platform in the future.
Looking to help bolster the media industry’s ability to measure its audience sizes, Veritone, Inc. (NASDAQ: VERI) claims that AI can help. During a webinar titled “An Exclusive Debrief: Using AI to Solve Broadcast Media’s Measurement Issue”, Paul Cramer, Managing Director of Media and Broadcast at Veritone spoke to several media members in the audience, to address how AI can help through content intelligence, and advertising intelligence.
“For those of you who aren’t familiar with Veritone, we help you manage and monetize your content using AI, and we work with over 2, 000 media brands in six countries across cultural environments,” said Cramer, noting those brands include CBS News, CNBC, CNN, CNBC, Cox Radio and Television, Hearst Television, iHeartMedia and NBCUniversal.
Veritone recently announced it had enhanced its Advertising and Content Intelligence Suite to support future-proofing of client broadcast revenues. Their Advertising and Content Intelligence Suite offers a robust collection of AI-driven tools that enhance content management, advertising strategies, and audience engagement for media companies, advertisers, and broadcasters. The suite utilizes the aiWARE enterprise AI platform to deliver comprehensive capabilities in media monitoring, content discovery, ad verification, and analytics.
“Veritone’s latest enhancements to our Advertising Content and Intelligence Suite empower our clients to adapt to new AI-powered media management methodologies and lead with sophisticated tools that help them to increase their ad revenue,” said Sean King, General Manager for Veritone Media and Entertainment. “Our new enhancements prioritize data privacy and security and provide broadcasters with nearly instant insights, enabling them to make data-driven connections between ad placement and audience impact.”
Article Source: https://usanewsgroup.com/2024/04/26/the-currency-of-tomorrow-why-investing-in-cutting-edge-ai-recognition-tech-could-mean-big-money/
CONTACT:
USA NEWS [email protected](604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Scope AI Corp. advertising and digital media from the company directly. There may be 3rd parties who may have shares Scope AI Corp., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Scope AI Corp. which were purchased as a part of a private placement. MIQ reserves the right to buy and sell, and will buy and sell shares of Scope AI Corp. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through further private placements and/or investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
View original content:https://www.prnewswire.co.uk/news-releases/generative-ai-market-set-for-meteoric-rise-expected-to-reach-266-billion-by-2032-302136924.html
-
Artificial Intelligence3 days ago
CleverTap launches Clever.AI, the AI-Driven Edge for Customer Engagement & Retention
-
Artificial Intelligence7 days ago
SUNRATE partners with YeePay to empower Chinese companies to navigate global expansion
-
Uncategorized4 days ago
Improving the Developer Journey in Crafting Artificial Intelligence Applications
-
Uncategorized7 days ago
Intel unveils AI-Platform Innovation for Paris 2024
-
Artificial Intelligence5 days ago
Appdome Unveils World’s First Agentless Mobile EDR & MTD
-
Uncategorized4 days ago
Unveiling the Complex Psychological Implications of Artificial Intelligence
-
Artificial Intelligence4 days ago
Bitrue expands Bitcoin Runes Offerings with GPTV Listing and Staking Options
-
Artificial Intelligence4 days ago
5G Enterprise Market Projected to Reach $115.81 billion by 2030 – Exclusive Report by 360iResearch